Amivantamab (Rybrevant): Targeted Lung Cancer Guide

Introduction

Non-small cell lung cancer (NSCLC) is increasingly treated according to the molecular profile of the tumor rather than by diagnosis alone. One important example is EGFR-mutated NSCLC, including EGFR exon 20 insertion mutations and more common mutations such as exon 19 deletion and L858R.

Amivantamab, marketed as Rybrevant, is a targeted biologic therapy. It is not conventional chemotherapy. It is designed to bind two receptors involved in cancer growth and resistance: EGFR and MET. This article is organized as a practical decision guide: who may be eligible, what the treatment may do, what side effects matter, and what remains investigational.

What Is Amivantamab and How Does It Work?

Mechanism of Action

Amivantamab is a fully human bispecific IgG1 antibody. One molecule can bind two biologic targets: EGFR and MET.

The key point: amivantamab is not appropriate for every person with lung cancer. Eligibility depends on cancer type, stage, prior therapy, performance status, local approval and the tumor's molecular test result.

FDA Approvals: A Timeline

Key United States approvals

It is important to separate regulatory approval from research results. For example, use in head and neck cancer should not be presented as a routine approved indication for all patients.

Key Clinical Trials

PAPILLON: first-line EGFR exon 20 insertion NSCLC

PAPILLON tested amivantamab plus chemotherapy versus chemotherapy alone in advanced NSCLC with EGFR exon 20 insertion mutations. The main finding was improved time without disease progression.

MARIPOSA: common EGFR mutations

MARIPOSA evaluated amivantamab plus lazertinib against standard osimertinib in patients with common EGFR mutations, such as exon 19 deletion or L858R. The goal was to test whether dual targeted treatment could delay progression.

CHRYSALIS: early efficacy foundation

CHRYSALIS provided early response data, especially in previously treated patients. It was important for the first approvals, but it does not replace larger phase 3 trials.

OrigAMI-4: Amivantamab in Head and Neck Cancer (ASCO 2026 : Breaking News)

What was reported at ASCO 2026

OrigAMI-4 evaluated subcutaneous amivantamab in recurrent or metastatic HPV-unrelated head and neck squamous cell carcinoma after progression on immunotherapy and chemotherapy.

The reported results showed a relatively high response rate in a difficult-to-treat population. Some patients had substantial tumor shrinkage, and some were reported to have a complete response.

Responsible wording for an article

For a lung cancer article, this should be a short contextual section: amivantamab is approved in specific lung cancer settings and is also being studied in other tumors.

Does Amivantamab Shrink Tumors?

Yes, in some patients amivantamab can shrink tumors or delay disease progression. Response is not guaranteed and depends on the mutation, disease stage, prior treatments and the patient's overall condition.

What the result may mean for a patient

Even with a strong response, patients need imaging follow-up, blood tests, side-effect monitoring and ongoing treatment decisions.

Side Effects and Safety Profile

Amivantamab has a characteristic safety profile. Some side effects are related to EGFR blockade, while others are related to administration or the biologic mechanism.

A key warning sign is new or worsening shortness of breath. In that situation, patients should contact the treatment team urgently rather than waiting for the next appointment.

Amivantamab vs. Other EGFR-Targeted Treatments

Basic comparison

There is no single best treatment for every patient. Choice depends on molecular profile, treatment line, comorbidities, performance status, patient preferences and local availability.

Integrative (Complementary) Medicine and Amivantamab

Integrative oncology may help with fatigue, anxiety, pain, nausea, nutrition and sleep, but it does not replace cancer-directed treatment.

Options to discuss with the care team

• Moderate physical activity as tolerated.
• Oncology nutrition counseling.
• Skin and nail supportive care.
• Breathing and relaxation techniques.
• Psychological support or support groups.

What to avoid

Supplements, herbal products and high-dose antioxidants may interact with medication or affect safety monitoring. Patients should not start a supplement during amivantamab treatment without approval from the oncologist or clinical pharmacist.

Who Is a Candidate for Amivantamab?

Amivantamab is appropriate only for selected patients, not based on the diagnosis name alone.

Usually required

1. A diagnosis of advanced or metastatic NSCLC.
2. Molecular testing showing a relevant EGFR mutation.
3. Fit with the approved indication in the country of treatment.
4. Review of prior treatments, comorbidities and overall performance status.
5. Discussion with an oncologist about expected benefit, risks and alternatives.

Questions to ask the oncologist

• Which exact mutation was found?
• Is this treatment intended for first-line use or after prior therapy?
• Will it be given as an infusion, subcutaneous injection or with other drugs?
• Which side effects require urgent contact?
• How often will CT or PET-CT scans be used for follow-up?

Frequently Asked Questions (FAQ)

Is amivantamab chemotherapy?

No. Amivantamab is a targeted biologic therapy called a bispecific antibody. In some indications, however, it is given together with chemotherapy.

Does amivantamab cure lung cancer?

In metastatic disease, it is generally not described as curative. The goals are tumor shrinkage, delaying progression, extending progression-free time and improving disease control.

Is genetic testing needed before treatment?

Yes. Molecular testing is essential to determine whether a patient is likely to be eligible.

Is it also used for head and neck cancer?

Current head and neck cancer data are based on clinical studies and should not be presented as a routine indication for all patients.

When should a patient seek urgent care?

New shortness of breath, fever, worsening cough, chest pain, severe rash, facial swelling or an unusual reaction during treatment should prompt rapid medical contact.

Living With Amivantamab: Practical Patient Guidance

Before starting treatment

• Keep a copy of the molecular testing report.
• Prepare a list of medications, supplements and allergies.
• Ask how treatment will be given: infusion, injection or combination therapy.
• Understand which side effects are expected and which are dangerous.

During treatment

• Report rash, diarrhea, shortness of breath or nail pain early.
• Avoid starting new supplements without approval.
• Maintain hydration and nutrition according to the care team's advice.
• Attend scheduled monitoring visits.

Practical tip

Keep a short treatment diary: treatment day, side effects, temperature, breathing symptoms, medications taken and questions for the oncologist. This helps the team make more accurate decisions.

What to Expect Next: Future Directions

Future directions for amivantamab include earlier use, combinations with other therapies, more convenient formulations and personalization according to tumor biology.

Additional studies are evaluating the drug in lung cancer and other tumors, including head and neck cancer. However, every expanded use requires adequate data and appropriate regulatory approval.

The practical message: if an EGFR mutation is found, ask the oncologist whether targeted therapy is appropriate, whether a better alternative exists and whether a relevant clinical trial is available.

Medical Disclaimer

This article is for general information only and does not constitute medical advice, diagnosis or treatment recommendation. Decisions about amivantamab, Rybrevant or any oncology treatment must be made with a qualified oncologist according to the patient's condition, test results, approved indications and local availability.